These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2013442)

  • 21. Potentiation of myocardial salvage by tissue type plasminogen activator in combination with a thromboxane synthetase inhibitor in ischemic cat myocardium.
    Lefer AM; Mentley R; Sun JZ
    Circ Res; 1988 Sep; 63(3):621-7. PubMed ID: 3136950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of RO-22-4679, a thromboxane synthetase inhibitor, on ventricular fibrillation induced by coronary artery occlusion in conscious dogs.
    Huddleston CB; Lupinetti FM; Laws KH; Collins JC; Clanton JA; Hawiger JJ; Oates JA; Hammon JW
    Circ Res; 1983 May; 52(5):608-13. PubMed ID: 6682723
    [No Abstract]   [Full Text] [Related]  

  • 23. Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis.
    Olson RW; Dotson R; Mathis J; Cohen DS; Webb RL
    Eur J Pharmacol; 1993 May; 236(1):75-87. PubMed ID: 8319746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vasoconstriction with thromboxane A2 induces ulceration of the gastric mucosa.
    Whittle BJ; Kauffman GL; Moncada S
    Nature; 1981 Jul; 292(5822):472-4. PubMed ID: 7195986
    [No Abstract]   [Full Text] [Related]  

  • 25. CGS 15435A, a thromboxane synthetase inhibitor with an extended duration of action: a comparison with dazoxiben.
    Olson RW; Cohen DS; Ku EC; Kimble EF; Renfroe HB; Smith EF
    Eur J Pharmacol; 1987 Jan; 133(3):265-73. PubMed ID: 3104066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of S-antigen-induced experimental autoimmune uveoretinitis in Lewis rats by oral administration with CGS-13080, a thromboxane synthetase inhibitor.
    Li Q; Lopez JS; Caspi RR; Roberge FG; Nussenblatt RB; Kador PF; Chan CC
    Exp Eye Res; 1993 Nov; 57(5):601-8. PubMed ID: 8282047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of selective inhibitor of thromboxane A2 synthetase on experimental cerebral vasospasm.
    Fukumori T; Tani E; Maeda Y; Sukenaga A
    Stroke; 1984; 15(2):306-11. PubMed ID: 6538355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imidazo[1,5-a]pyridines: a new class of thromboxane A2 synthetase inhibitors.
    Ford NF; Browne LJ; Campbell T; Gemenden C; Goldstein R; Gude C; Wasley JW
    J Med Chem; 1985 Feb; 28(2):164-70. PubMed ID: 3918169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thromboxane synthesis inhibition and postprandial intestinal hyperemia and oxygenation.
    Mangino MJ; Chou CC
    Am J Physiol; 1986 Jan; 250(1 Pt 1):G64-9. PubMed ID: 3942214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben.
    Butler KD; Butler PA; Shand RA; Ambler J; Wallis RB
    Thromb Res; 1987 Mar; 45(6):751-61. PubMed ID: 3109067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thromboxane synthetase inhibition in primary pulmonary hypertension.
    Rich S; Hart K; Kieras K; Brundage BH
    Chest; 1987 Mar; 91(3):356-60. PubMed ID: 3545698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of a specific thromboxane synthetase inhibitor on thromboxane generation and excretion in healthy dogs.
    Longhofer SL; Johnson HC; Culham CA; Schultz KT; Grauer GF
    Am J Vet Res; 1990 Nov; 51(11):1746-50. PubMed ID: 2240799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase.
    Reilly IA; Doran JB; Smith B; FitzGerald GA
    Circulation; 1986 Jun; 73(6):1300-9. PubMed ID: 2938849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the thromboxane synthesis inhibitor CGS-12970 on experimental acute renal allograft rejection.
    Mangino MJ; Brunt EM; Von Doersten P; Anderson CB
    J Pharmacol Exp Ther; 1989 Jan; 248(1):23-8. PubMed ID: 2643702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effects of a thromboxane synthase inhibitor or prostacyclin in combination with a phosphodiesterase inhibitor for prevention of experimental thrombosis and sudden death in rabbits.
    Smith EF; Egan JW
    J Pharmacol Exp Ther; 1987 Jun; 241(3):855-60. PubMed ID: 3298621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
    De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Vercammen E; Freyne E; Janssen PA
    Prog Clin Biol Res; 1989; 301():567-72. PubMed ID: 2529556
    [No Abstract]   [Full Text] [Related]  

  • 38. Thromboxane synthetase inhibitors reduce infarct size by a platelet-dependent, aspirin-sensitive mechanism.
    Mullane KM; Fornabaio D
    Circ Res; 1988 Apr; 62(4):668-78. PubMed ID: 3127073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacology of thromboxane synthetase inhibitors.
    Smith JB
    Fed Proc; 1987 Jan; 46(1):139-43. PubMed ID: 3542573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.
    Fitzpatrick FA; Gorman RR
    Biochim Biophys Acta; 1978 Mar; 539(2):162-72. PubMed ID: 629996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.